Figure 2.
Trends in PCSK9 inhibitor prescriptions, July 2015 to March 2017. PCSK9 inhibitor prescription rates with 95% CIs during 6‐month intervals except the final reported time period (January–March 2017), which represents only 3 months. CAD indicates coronary artery disease; CHD, coronary heart disease; PCSK9, proprotein convertase subtilisin/kexin type 9.